Podcasts about regulatory

America Out Loud PULSE with Dr. Randall Bock – Opioid maintenance treatment raises questions about how medicine defines recovery. Regulatory pressure, medical education, and financial incentives favor continued enrollment, while pathways toward ending treatment receive less attention. The debate centers on whether success means retaining patients indefinitely or helping them pursue independence from treatment...

FREE preview available to all visitors. Full on-demand broadcast of The Mike Church Show, presented without commercials for PREMIUM members.

Send us Fan MailGuest BioGia Sawko | Chief Claims Officer at Signal MutualDecades of claims experience in workers' compensationInstrumental in navigating how AI reshapes the adjuster's roleFocused on preserving and amplifying human judgment in claims workThe ConversationYvonne, Rafael, and Gia get into what's happening in claims work right now. The job is harder than ever. The tools haven't caught up. And there's a path forward if we're willing to think differently about training, technology, and what we ask of the people doing this kind of work.Key Discussion PointsThe Claims Desk Hasn't Been Redesigned in 20+ YearsThe claims adjuster's job has become exponentially more complex. Medical knowledge requirements have expanded. Regulatory demands keep multiplying, and they're harder than ever to navigate. Case management now demands synthesis across medical history, pharmacy data, functional capacity, and emerging compensability questions. But the actual desk, the systems, and the workflows look almost identical to what they did two decades ago. The infrastructure hasn't kept pace with our industry's complexity.Why Don't We Train Claims Adjusters Like Apprentices?Gia makes a good point: we should treat claims adjuster development like other industries treat apprenticeships, such as skilled trades. New adjusters need structured mentorship, graduated complexity, and time to build judgment alongside technical knowledge. Right now, they often get thrown into the deep end. If we reimagined onboarding the way apprenticeship programs do, with clear progression and accountability, we'd build stronger professionals. People who feel accomplished master their craft and stay in the industry.AI as Support, Not ReplacementThe highest-value use of AI in claims isn't automation; it's augmenting what adjusters already do. AI can flag high-risk claims and surface comorbidities. It can summarize documents. But the adjuster owns the relationship with the claimant and the critical judgment calls. The combination between the person and the algorithm is where we'll get the best outcomes.Implementation Challenges Are RealYou can't pause operations to implement AI. Decision fatigue is a risk when adjusters get too many warnings. And AI is only as good as the question asked. We need to teach adjusters how to ask better questions and build trust through testing. This is the "how" nobody's really solved yet.AI Literacy Is Non-NegotiableEvery adjuster needs to become proficient in AI language now. Start small, test on easy tasks, validate against what you already know. Those who build this proficiency will be positioned better than those who don't. The window is now.Deucing Every PointGia is a serious tennis player! Ask her about a match where she lost 6-0, 6-0—and she'll tell you about the deuces, the rallies that mattered, the quality of every point. Lean in to hear what the court might teach us about adjuster mastery.¡Muchas Gracias! Thank you for listening. We would appreciate you sharing our podcast with your friends on social media. Find Yvonne and Rafael on Linked In or follow us on Twitter @deconstructcomp 

Nataraj speaks with Mike Collins, founder of Alumni Ventures, about how his firm opened up venture capital to individual investors through pooled funds and co-investing. They also dig into the structural problems in private markets, why companies stay private longer, and how AI is reshaping venture without eliminating the need for patience, judgment, and diversification.Key topicsMike Collins' background in ventureWhat Alumni Ventures is built to doHow the alumni fund model worksWhy diversification matters in ventureThe long-term nature of venture investingProblems in today's venture and public marketsWhy companies stay private longerAI, hype, and real innovationWhy adoption is slower than demosHow new venture firms get startedLearning resources for retail investorsTimestamps00:00 - Introduction and why Alumni Ventures matters00:24 - Mike Collins' VC background and founding Alumni Ventures01:24 - The mission: access and education for individual investors03:59 - How an alumni fund is structured and invested05:55 - Why pooled capital and network scale matter06:24 - Venture capital as a core engine of the economy07:28 - Why most individuals need private-company exposure08:51 - Why venture portfolios need diversification10:33 - Green D fund leadership and how team sourcing works11:52 - How deals get allocated across multiple funds13:11 - Venture as a long-term, slow-compounding asset class14:07 - Building a venture allocation over several years15:04 - Why checking investments too often looks like trading16:44 - The biggest accessibility problem in venture today17:42 - Why public-company incentives have weakened18:43 - Why companies delay going public20:16 - Late-stage private companies and who captures the upside21:14 - Why SpaceX illustrates the privatization of gains22:51 - Public versus private markets and the role of competition24:19 - AI as a real platform shift, not just hype26:15 - Big opportunities beyond AI: energy, defense tech, healthcare27:41 - The cultural bias toward doom and negative headlines29:37 - Why staying private can help companies like Stripe32:40 - How AI capital concentration affects the broader venture market34:53 - The Series A squeeze and how market corrections happen36:49 - The main paths to starting a new venture fund39:15 - Why great companies still take decades to build40:29 - Why AGI timelines are often faster in theory than in reality42:24 - Regulatory backlash and the slower pace of adoption43:18 - Self-driving cars as a cautionary example for AI timelines44:54 - Why the last 5 percent of product adoption is the hardest46:58 - AI as a tutor for learning venture capital47:53 - Books and frameworks for understanding startups and VC49:18 - How to filter noise and think in decades, not days50:44 - Why the best investors often do the least trading51:50 - Mike's core investing rules and closing thoughts

Good morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of pivotal advancements and strategic maneuvers shaping the landscape of drug development and patient care. Bayer's Kerendia, known generically as finerenone, has achieved its third FDA approval, this time targeting chronic kidney disease linked with type 1 diabetes. This small molecule mineralocorticoid receptor antagonist plays a critical role in mitigating fibrosis and inflammation—key factors in chronic kidney disease progression. Given the high prevalence of kidney complications in diabetic patients, this approval marks a significant step forward in managing such conditions. Its mechanism offers a novel approach to addressing cardiovascular and metabolic disorders, underscoring its vital role in contemporary therapeutic strategies. In regulatory advancements, AstraZeneca and Daiichi Sankyo's Enhertu has secured approval from NICE for treating HER2-low breast cancer. This marks a significant transition toward precision medicine, allowing the NHS to provide more targeted cancer therapies. Enhertu, an antibody-drug conjugate, exemplifies the shift towards precision oncology by delivering cytotoxic agents directly to cancer cells expressing HER2, thus opening new avenues for personalized treatment strategies. Japan's MHLW has given the green light to GSK's Shingrix in prefilled syringe form for shingles prevention. As a recombinant zoster vaccine enhanced by an adjuvant system, Shingrix represents cutting-edge vaccine technology aimed at strengthening immune responses against the varicella-zoster virus. This approval not only broadens preventative measures but also highlights advancements in vaccine delivery systems. Novo Nordisk's collaboration with Orbis Medicines is another noteworthy development, focusing on oral macrocycle therapies for cardiometabolic conditions—a partnership with potential milestones valued at $1.4 billion. This move aligns with Novo Nordisk's strategic push into small molecule drug discovery to address unmet needs in cardiovascular and metabolic disorders, echoing a broader industry trend towards innovative therapeutic approaches. Meanwhile, Roche has ventured into an agreement with Dualitas Therapeutics to develop bispecific antibody platforms for autoimmune diseases. With an upfront payment of $36.5 million and potential milestone payments reaching $1 billion, this collaboration underscores the burgeoning interest in bispecific antibodies' capacity to target dual antigens simultaneously—offering promising new pathways for treating complex immunological conditions. On the clinical trial front, Roche's Lunsumio has met its Phase 3 primary endpoint, showcasing improved progression-free survival in patients with relapsed or refractory follicular lymphoma. This bispecific antibody exploits the immune system by targeting CD20 on B-cells while engaging CD3 on T-cells, highlighting its potential as an effective option for difficult-to-treat cancers. Conversely, Longeveron's laromestrocel faced setbacks in its Phase 2b trial for hypoplastic left heart syndrome—a reminder of the complexities inherent in developing cell therapies for cardiovascular diseases. Such challenges highlight the critical need for innovative approaches and continued perseverance within clinical development. Regulatory scrutiny remains a pertinent issue as evidenced by the FDA's warning letter to Bausch & Lomb over contamination concerns. This action emphasizes ongoing challenges within ophthalmology manufacturing standards and regulatory compliance—critical aspects that demand rigorous attention to ensure patient safety. These developments collectively reflect an industry characterized by dynamic scientific advancements and strategic collaborations aimed at addressing pressing health challenges through cutting-edge drug development and precision medicine. As companies continue to invest in innovative research and form strategic alliances, these efforts offer significant promise for improving patient outcomes through more effective and targeted therapies. The evolving regulatory landscapes and technological advancements will undoubtedly shape these trends further, offering new opportunities for growth and breakthroughs in patient care. The commitment to overcoming complex challenges remains at the forefront of industry priorities as stakeholders strive to deliver impactful treatments to patients worldwide. Thank you for tuning into Pharma Daily; stay with us as we continue to explore these transformative developments shaping the future of healthcare science.Support the show

In this episode, we're joined by Matthew Taylor, a litigation lawyer with Sotos Class Actions in Toronto who represents retail investors and pension funds in securities class actions. We take a deep dive into what makes a successful negligence claim against a financial advisor, how courts assess fiduciary relationships in Canada, and what investors should look for when evaluating the people managing their money.   We explore the evidence that can strengthen or weaken a negligence claim, from one-size-fits-all portfolios and unexplained trades to poor communication and failures to account for changing life circumstances. Matthew also explains the distinction between suitability and fiduciary standards, the factors courts consider when determining whether a fiduciary relationship exists, and why professional affiliations and explicit fiduciary commitments can matter.   The conversation then turns to class actions, including how securities claims differ from individual negligence lawsuits, what makes a claim suitable for class proceedings, and why regulatory investigations, specialist law firms, litigation funding, and parallel U.S. proceedings can provide important signals. We also discuss pension funds, their role as plaintiffs, and why monitoring potential claims and settlements can be part of managing beneficiaries' assets.   Finally, we examine the growing retailization of private assets and the risks created by limited information, complex structures, opaque fees, illiquidity, and manager-determined valuations. Matthew explains what advisors and clients should consider before investing in private funds—and why he expects more litigation in this area. We close with the legal and regulatory challenges created by financial influencers, and how investors and advisors can build greater resilience against misleading financial content. Key Points From This Episode: (0:01:04) Advisor errors leading to negligence claims—KYC, KYP, suitability failures, plus warning signs like one-size-fits-all portfolios, unexplained trades, concentrated positions, churning, and double dipping. (0:02:20) Why evidence matters: the gap between what people know and what they can prove in court.  (0:04:08) How investors can recognize poor advice—changes in communication, failure to address life circumstances, or lack of transparency.  (0:06:41) Importance of checking an advisor's regulatory history before entrusting significant assets.  (0:07:51) Investor vulnerabilities: age, education, language barriers, or sudden wealth.  (0:11:27) Steps after negligent advice—seek a second opinion, adjust the portfolio, and consider legal recourse quickly due to limitation periods.  (0:13:30) Risk capacity vs. risk tolerance, and overlooked risks such as liquidity, sequence-of-returns, and withdrawal risk.  (0:16:34) Advisors' uneven understanding of risk, shaped by firm/product-provider education and low industry entry barriers.  (0:19:48) Courts' five fiduciary factors—vulnerability, trust, reliance, discretion, and professional standards—and how fiduciary duties differ from suitability standards.  (0:28:28) Individual lawsuits vs. group/class actions, with securities class actions focusing on disclosure problems and asset-manager claims.  (0:42:45) Case studies: Sino-Forest fraud and challenges of private assets—opaque structures, layered fees, liquidity risk, and valuation issues.  (1:01:00) Regulatory challenges of finfluencers, difficulties in enforcement, and how advisors can inoculate clients against misinformation by teaching evaluation skills. Sources From Today's Episode — https://zbib.org/71e494008bb74d18a17de20419ca0647 Links From Today's Episode: Meet with PWL Capital: https://pwlcapital.com/  PWL Team — https://pwlcapital.com/our-team/ Rational Reminder on Spotify — https://open.spotify.com/show/6RHWTH9iW7hdnA7eAg7ukO?si=fe7f60349b584026 Rational Reminder on iTunes — https://itunes.apple.com/ca/podcast/the-rational-reminder-podcast/id1426530582. Rational Reminder on Instagram — https://www.instagram.com/rationalreminder/ Rational Reminder on YouTube — https://www.youtube.com/channel/ Benjamin Felix — https://pwlcapital.com/our-team/ Benjamin on X — https://x.com/benjaminwfelix Benjamin on LinkedIn — https://www.linkedin.com/in/benjaminwfelix/ Matthew on LinkedIn — https://www.linkedin.com/in/matthew-w-taylor/ Geller Law — Legal Legacy - Webflow Ecommerce Website Template Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com)  

Mentor Sessions Ep 096: Zack Shapiro explains AI existential risk, AI regulation, the Clarity Act, Samurai Wallet, and open source AI policy for Bitcoin.The Clarity Act just failed on the Senate floor, and the fight over whether writing Bitcoin code can be treated as a crime is now heading to 70-year-old federal judges. Zack Shapiro breaks down what that means for self-custody, open source software, and the Samurai Wallet developers still behind bars.In this conversation you'll learn why Zack separates AI existential risk (recursive self-improvement, the orthogonality thesis, instrumental convergence) from the ordinary risks of AI — job displacement, regulatory capture by frontier labs, and cyber attacks like the Cold Card hack. You'll see why he thinks open source AI is not the existential threat, why the Blockchain Regulatory Certainty Act (BRCA) matters more than most Bitcoiners realize, and how the 'two clocks' of AI capability vs enterprise adoption will define the next decade. You'll also get the legal reality behind white hat recovery of hacked Bitcoin, why the liquid hacker is in a bad spot, and what happened when the Clarity Act died on the vine.⏱️ Timestamps:0:00 - Intro0:51 - Amodei, Musk and Altman urge AI slowdown1:38 - Ordinary risks versus existential AI threats2:26 - Politics warping the AI safety debate3:20 - Bostrom, AGI and intelligence explosion risks5:01 - Orthogonality thesis and instrumental convergence5:59 - Hugging Face attack shows AI covering tracks6:58 - No easy policy fixes for AI risks8:08 - Can't stop AI progress or open source China9:32 - Separating x-risk concerns from anti-AI populism12:22 - Regulatory capture and Anthropic IPO timing14:21 - Keeping open source AI legal and available16:39 - Trezor self-custody sponsor read17:43 - One shot parallel between Bitcoin and AI19:37 - Where real AI productivity gains appear20:47 - Two Clocks: capability versus enterprise adoption24:22 - Is AI coming for your job?25:28 - Electrification analogy and 30-year lag28:34 - Jevons Paradox and future of work30:42 - White hat recovery of Cold Card hacked funds34:02 - Legal precedent for white hat bounties36:56 - Why the Liquid hacker faces trouble38:55 - What's actually in the Clarity Act43:46 - Money transmitter law and the Samurai case45:20 - Tornado Cash, FinCEN and frying pan argument47:31 - Why this could ban using Bitcoin49:33 - BRCA criminal protections and court battles53:42 - Clarity Act fails to pass what happened55:24 - Senator Lummis stood on principle56:50 - Where to follow Zack ShapiroGuest: Zack Shapiro — lawyer and AI-native law firm builder covering crypto policy, AI regulation, and Bitcoin legal defense.

Week two with the Playlist Bros, as Michael and Anthony discuss How To Talk About the sudden AI Panic! Over the weekend, Anthropic CEO Dario Amodei sounded the alarm for the need to slow down AI development and something crazy happened...all the other tech bros agreed! Well, sort of...they all agreed AI is developing way too quickly, but we must compete with China and they're not regulating themselves. So how do we do it? Later on the episode, we segue to the Politician On Our Playlist this week: Congressman Wesley Hunt, of Texas, who's been tapped by Trump to serve as US Ambassador in Saudi Arabia. He'll need a Senate confirmation first, but those guys seem to be giving a rubber stamp on everything. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ted returns from New Zealand to join Pav for a crucial breakdown of regulatory milestones and macro developments shaping digital asset markets. In this episode, Pav and Ted dissect the collapse of Hunter Biden's celebrity meme token, which plummeted 99% within an hour of launch. They unpack top weekly movers, focusing on Betway (BTW) and its yield-generating DeFi strategies backed by Tron Foundation, VVV's AI inference model, and PancakeSwap's surging $75M daily volume in tokenised stock trading. The boys also dive deep into the US Senate floor vote on the long-awaited Clarity Act, updates regarding the proposed US Strategic Bitcoin Reserve, and upcoming rate hike decisions across the US, Japan, and Australia. Key Moments: 00:00 Ted's Queenstown highlights and Waiheke Island wineries. 01:30 Hunter Biden $Laptop Token Collapse: Analyzing fully diluted valuations and celebrity token risks. 06:01 Institutional yield strategies, Tron backing, and decentralized AI inference. 10:05 Real-world assets (RWAs) and processing $75M in daily volume. 12:37 Clarity Act Senate Vote: Final draft revisions, bipartisan hurdles, and Polymarket sentiment shifts. 21:40  Central bank updates from the US, Japan, and Australia. 26:43 Treasury Secretary Scott Bessent's push for government BTC holdings. Want to see what we're looking at every episode? Watch the YouTube version of the podcast here. Ready to start? Get $10 of FREE Bitcoin on Swyftx when you sign up and verify:  https://trade.swyftx.com.au/register/?promoRef=tappingintocrypto10btc  To get the latest updates, hit subscribe and follow us over on the gram @tappingintocrypto or X @tappingintocrypto If you can't wait to learn more, check out these blogs from our friends over at Swyftx. This podcast provides general market commentary and is for educational and entertainment purposes only. It is NOT financial advice. We are NOT licensed financial advisors. Investing in cryptocurrency carries risk. You should always conduct your own research and seek independent financial advice before making any investment decisions. Please read Swyftx's Terms and Conditions and Risk Disclosure statement before investing.

The following article of the Policy & Economy industry is: 'Sheinbaum's Environmental Reform: Key Advances, Regulatory Risks' by Gabriel Quadri, Asesor, SIGEA. 

Scott Wapner and the Investment Committee debate what the growing chorus of AI safety fears means for the sector and the broader market. CNBC's Kate Rooney joins us to discuss the latest news on AI's regulatory divide. Plus, Rick Rieder, Blackrock's Global Fixed Income CIO, joins us to discuss the Fed, rate hikes, the markets and more. And later, the desk detail their latest portfolio moves. Investment Committee Disclosures Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Ashley Morgan, DVM, CAE, AAEP director of equine welfare and advocacy, joined us to discuss the AAEP Advocacy Network and some of the latest legislative and regulatory developments that could impact the veterinary profession.To access more advocacy resources and webinars or find opportunities to weigh in on emerging issues, you can contact Dr. Morgan at amorgan@aaep.org.The Business of Practice podcast is brought to you by CareCredit.This information is shared solely for your convenience. You are urged to consult with your individual advisors with respect to any information presented.Business of Practice Podcast Hosts, Guests, and Links Episode 148:Hosts: Dr. Amy Grice and Carly Sisson (Digital Content Manager) of EquiManagement | Email Carly (csisson@equinenetwork.com) | Connect with Carly on LinkedInGuests: Dr. Ashley Morgan, DVM, CAE, AAEPPodcast Website: The Business of Practice

From the open to the close, “Closing Bell” and “Closing Bell: Overtime” have you covered. From what's driving market moves to how investors are reacting, Scott Wapner, Melissa Lee and Michael Santoli guide listeners through each trading session and bring to you some of the biggest names in business.  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Elisa Wood, founder and editor of the newsletter Energy Changemakers, has covered the evolution of consumer-empowering technologies such as microgrids, demand response, rooftop solar and battery storage and vehicle-to-grid for more than a dozen years. There is perhaps no one more qualified to discuss these emerging consumer-empowering electricity options and the forces working against their adoption.In a wide-ranging discussion, Wood notes the headwinds facing these technologies but is overall optimistic about the future. The traditional regulatory framework for monopoly utilities, a vestige of the 19th century, rewards utilities for building big projects that provide shareholders big returns under the rate-regulated model, leaving these corporations with little financial incentive to invest in these smaller-scale technologies. Nevertheless, while there's little near-term prospect of changing the regulatory paradigm, Wood is optimistic that technology will ultimately drive change."I think that the champion is technology," Wood says. "You have commercial/industrial customers putting in microgrids, even though it's not a real hot year for them. It's going to come back, and you've got virtual power plants, you know, coming to the fore. Community solar coming to the fore. All these things are competing with utilities. So the competition came. I think it just came through new technology, and I think that's only going to grow. Those technologies aren't going away."Another driver is rising electricity costs, which have become an election-year issue. "I think we're on the verge of something big," she says. "It's a tough time because the Trump administration, you know, has gotten rid of incentives and whatnot and kind of created a lot of tumult for the industry . . . but I feel like the consumer impetus is there and the technology is there waiting for it. So I'm actually pretty bullish right now."Wood sees all of these multiplying technologies "eating away" at the hold giant utilities have on the system, noting increasing consumer interest and municipalities investing in these technologies, which is creating a bottom-up approach to changing the utility system, more so than regulatory reforms. Regulatory reform is "really hard because (utilities) have the lobbyists," she says. "They have all the money to go in there to the regulatory agencies and influence them. And who can possibly compete with that? Who's out there that can compete with that? There's really no other entity, right? So regulation has to be changed from another direction. And I really believe it's going to be from more the consumer choosing something else and forcing the utility to change, or basically taking away their customer base, you know, so that they have to change. I think it's going to come from that direction."Support the show

A breakthrough in drug discovery can be derailed in an instant if manufacturability is left as an afterthought. Too many biotech programs hit bottlenecks at scale-up because key decisions in cell line and process development get kicked down the road.On the Smart Biotech Scientist Podcast, David Brühlmann spoke with Sigma Mostafa, Chief Scientific and Technology Officer at KBI Biopharma. She's spent 25+ years converting early-stage discoveries into commercial biomanufacturing success and she's adamant: manufacturability decisions belong at the candidate selection stage, not after.Topics discussed:Why manufacturability should be assessed at the candidate selection stage, not later (03:02)Sigma's background in bringing math and biology together and her path into bioprocess engineering (04:18)The "art" and complexity of bioprocess development, especially with new molecule types (05:54)A case study of how switching cell lines revealed hidden manufacturability issues (07:33)Key properties affecting manufacturability, such as aggregation and thermal stability (10:10)Reasons companies delay manufacturability assessments—timing pressure, costs, and lack of early deep characterization (11:02)Why CMC should be integrated from day one and concerns with treating scalability as 'just' engineering (12:08)Critical decisions and pitfalls in cell line development, including robustness, media choices, and adapting after the master cell bank is made (12:48)Regulatory aspects of cell line development: demonstrating clonality, avoiding animal source materials, and documentation requirements (15:04)Smart insight: Manufacturability is not just a box for the CMC team. It's a proactive mindset, to be embraced from day one. Early, cross-functional scrutiny—examining both molecule and cell line—preempts disasters during scale-up and accelerates timelines to market while minimizing costly surprises.This episode unpacks what that means in practice and where speed and robustness pull against each other. If it resonated, these conversations expand the picture: how to spot manufacturable candidates early, how in silico tools predict stability and aggregation before the lab, and which early CMC decisions quietly become permanent.Episodes 123 - 124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan SharfsteinEpisodes 213 - 214: From Developability to Formulation: How In Silico Methods Predict Stability Issues Before the Lab with Giuseppe LicariEpisodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri KornmannEpisodes 103 - 104: One-Stop Shop vs. Specialist CDMO: A Scientist's Guide to CDMO Selection with Sigma MostafaConnect with Sigma Mostafa: Linkedin: https://www.linkedin.com/in/sigma-mostafa-79180817 KBI website: https://www.kbibiopharma.comFree 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it hereSupport the show

Rotterdam's record-low VLSFO sales reveal how quickly Europe's marine fuel market is being reshaped by forces at home and abroad. In this episode, Josh Michalowski (Diesel Reporter, Argus European Products) speaks with Bob Wigin (Fuel Oil Reporter, Argus European Products) about the changing balance between VLSFO and HSFO as RED III alters bunker economics and geopolitical disruption reshapes supply. Key themes: Regulatory impact on European bunker demand Middle East disruption redirects European VLSFO to Asia-Pacific Russian VGO tightness and marine fuel blending

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today's episode delves into some of the latest breakthroughs, regulatory updates, and strategic maneuvers reshaping the landscape of drug development and patient care. Starting with remarkable advancements in drug approvals, Scholar Rock's Isembldy (apitegromab), a monoclonal antibody designed to inhibit myostatin, has secured FDA approval for treating spinal muscular atrophy. This approval came after successful Phase 3 trials and marks a significant milestone in managing neuromuscular diseases. By targeting the myostatin pathway, which regulates muscle growth, Isembldy offers hope for improved motor function in patients suffering from this debilitating condition. Meanwhile, Pharming's Joenja (leniolisib) received an expanded label from the FDA, now approved for pediatric patients aged four and older with activated phosphoinositide 3-kinase delta syndrome, reflecting ongoing efforts to tackle rare autoimmune disorders. Telix Pharmaceuticals has also made strides with the approval of Pixclara (floretyrosine F 18) for PET imaging of glioma, enhancing diagnostic precision for both adult and pediatric brain cancer patients. In clinical trial successes and challenges, GSK and Hansoh Pharmaceutical reported that their antibody-drug conjugate, risvutatug rezetecan, significantly reduced the risk of death in Phase 3 trials for relapsed small-cell lung cancer by 54%. This underscores the potential of targeted therapies in oncology, especially where second-line treatments have been limited. AstraZeneca's Tagrisso (osimertinib), meanwhile, continued to demonstrate its efficacy with a notable reduction in death risk in early-stage EGFR-mutated non-small cell lung cancer at an eight-year follow-up, reinforcing its value as an adjuvant therapy. However, AstraZeneca faced setbacks with camizestrant's Phase 3 trial failing to meet primary endpoints in estrogen receptor-positive breast cancer. A similar challenge arose with Enhertu (trastuzumab deruxtecan) in HER2-mutant non-small cell lung cancer, indicating ongoing difficulties in developing effective combination therapies. Turning to strategic business developments, Johnson & Johnson's decision to divest its orthopedics unit DePuy Synthes to Apollo Equity Management for $20 billion reflects a strategic refocus on core areas like pharmaceuticals and medical devices. Similarly, Novo Nordisk's rebranding as 'Novo' signals an effort to strengthen its competitive stance against Eli Lilly within the GLP-1 agonist market, crucial for managing metabolic disorders such as diabetes. In collaborations and licensing deals aimed at broadening access to healthcare innovations, Bio Usawa's partnership with Axmed is set to enhance access to affordable biologic medicines across Africa, a vital step towards expanding healthcare reach in underserved regions. In oncology research advancements, Owkin has licensed its AI-driven K Pro scientist platform to Servier to accelerate drug discovery through artificial intelligence and machine learning applications. Regulatory challenges continue to shape industry dynamics. The FDA has postponed its decision on Exelixis's Zanzalintinib combined with Roche's Tecentriq for metastatic colorectal cancer until March 2027, reflecting rigorous scrutiny to ensure safety and efficacy. Meanwhile, Cellectis has opted to halt its allogeneic CAR-T programs amid increasing competition from in vivo approaches, showcasing strategic adaptability within the rapidly evolving field of cell therapy. In recent news focusing on mRNA technology and personalized cancer vaccines, Moderna's flu vaccine approval using mRNA technology marks a pivotal moment for this platform after facing skepticism over the years. Furthermore, Moderna and Merck have reported positive Phase 3 results for their personalized mRNA-based cancer vaccine—an advancement positioning them as leaders in personalized cancer immunotherapy following success in melanoma treatment. The sector remains dynamic as companies navigate these complex environments. Breakthroughs such as ivonescimab's success provide optimism for future innovations that could significantly enhance patient care and treatment outcomes across various diseases. The emphasis on mRNA technologies and personalized medicine heralds a new era of targeted therapies poised to redefine standards of care across multiple disease areas. As these initiatives progress, they hold potential not only for improving existing treatment paradigms but also for pioneering new frontiers in healthcare delivery. As these developments unfold, they highlight the industry's dual focus on advancing scientific innovation while navigating complex regulatory landscapes and competitive pressures. The implications are profound: promising enhanced patient outcomes through novel therapies while prompting strategic realignments among key industry players. These initiatives not only aim to improve existing treatment paradigms but also pioneer new frontiers in healthcare delivery.Support the show

Zac Prince is the Managing Director at Galaxy Digital and the co-founder and former CEO of BlockFi. In this conversation, we break down what really happened at BlockFi's collapse, the fraud behind FTX and Alameda that he witnessed firsthand, and the lessons he's applying to risk management today. We also discuss Galaxy One's banking, crypto, and yield products, and what the future of investing and AI-powered finance looks like.=======================The views expressed by the speakers are their own and do not necessarily reflect the views of Galaxy or its affiliates. Yield is variable and may change with 30 days' notice. Galaxy Premium Yield is available only to U.S. accredited investors, is not a bank deposit, and is not FDIC insured. The note is unsecured and may result in loss of principal. Guaranteed by Galaxy Digital Holdings LP, a subsidiary of Galaxy Digital Inc. Staking involves risks, including validator downtime, slash, loss of rewards, and Galaxy cannot guarantee validator performance.=======================Arch Public is an agentic trading platform that automates investment strategies across Stocks, Commodities, ETFs and Crypto. Whether you're rotating into AI & Gold, allocating to the S&P 500, or accumulating Bitcoin, Arch Public executes your plan 24/7 without ever taking custody of your assets or funds. Sign up today at https://www.archpublic.com, and start your FREE automated trading strategy! =======================TOKEN2049 returns to Singapore on October 7–8 at Marina Bay Sands. The world's largest crypto event. 25,000 attendees, 300 speakers, 1,000 side events and the whole industry in one place for two days, into the F1 weekend. Get 10% off your ticket with code POMP10 at https://token2049.com/singapore=======================Uphold is the easiest way to buy and sell crypto unlike any other platform allowing you to trade in just one step between any supported asset. Check them out at https://www.uphold.com/pomp/ This video includes a paid sponsorship with Uphold. I'm compensated by Uphold for promoting its products and services and may receive commissions from referrals. Terms apply. Not available in all jurisdictions. Digital assets are risky and may result in the total loss of your capital.=======================Simple Mining makes Bitcoin mining simple and accessible for everyone. We offer a premium white glove hosting service, helping you maximize the profitability of Bitcoin mining. For more information on Simple Mining or to get started mining Bitcoin, visit https://www.simplemining.io/pomp=======================0:00 - Intro1:05 - What really happened at BlockFi?8:09 - Celsius, Voyager collapse & the run on BlockFi10:01 - The FTX acquisition, Sam Bankman-Fried & discovering the fraud13:32 - Lessons applied to risk management at Galaxy16:08 - Silvergate, SVB & the "war on crypto"18:49 - Regulatory politics & the future of crypto policy22:10 - Rebuilding: what Zac learned post crypto war26:36 - What is Galaxy One? 41:43 - AI agents & the future of banking

Episode 534 00:00 Introduction 00:13 AI Fearmongering 02:30 Regulatory capture Big AI wants to write the legislation 04:02 SaaS is Back 04:28 AI pandemic type fearmongering: flatten the curve & wear a mask Sign up for free ALERTs & Market Commentary at:  https://www.investablewealth.com/subscribe/ ——————————————————

For episode 773 of the BlockHash Podcast, host Brandon Zemp is joined by Abdul Rafay Gadit, Co-founder of ZIGChain. ZIGChain is a permissionless Layer 1 blockchain, explicitly optimized for decentralized wealth management and the tokenization of real-world assets (RWAs).

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. First, let's delve into the innovative work being done by Grove Biopharma. Founded in 2020 in Chicago, this company is at the forefront of developing polymer-peptide hybrids to target intracellular protein-protein interactions, areas traditionally deemed undruggable. These interactions are crucial regulatory components in numerous cellular processes and are implicated in diseases like cancer and neurodegenerative disorders. However, their smooth protein surfaces present a challenge for traditional small molecule drugs, which struggle to find suitable binding pockets. Similarly, biologics like antibodies and peptides, despite their high binding affinities, face difficulties penetrating cell membranes due to their size and instability. Grove Biopharma addresses these issues through its proprietary Bionics Biologics™ technology. Developed by Nathan Gianneschi at Northwestern University, this approach uses protein-like polymers to mimic proteins with enhanced stability and cellular penetration. These polymers, adorned with peptide branches via living polymerization, maintain peptide binding properties while overcoming previous limitations in drug delivery. This breakthrough has already shown promise in preclinical studies. A 2023 study in Science Advances revealed the efficacy of targeting membrane protein CD36 for treating macular degeneration in mice, while a 2024 study demonstrated PLPs' ability to penetrate neurons and target mitochondria in Huntington's disease models. Moreover, a 2026 Nature Communications publication introduced HYDRAC, a new PLP class capable of degrading MYC and KRAS proteins, reducing tumor growth in mice. Grove Biopharma's pipeline is robust, targeting key areas in cancer and neurodegeneration. Despite challenges typical of the biotech landscape—such as toxicity concerns during clinical trials and scalability issues—Grove's unique platform offers the flexibility needed to address multiple targets effectively. Shifting focus to industry-wide developments, recent advancements highlight significant strides in personalized medicine. Moderna and Merck's mRNA cancer vaccine has shown promising results in a phase 3 study, marking an important step forward for customized healthcare approaches based on genetic profiles. This not only offers hope for cancer treatment but also signifies a wider shift towards more tailored therapeutic strategies. Regulatory updates also play a critical role in shaping industry dynamics. The appointment of Dr. Angelo De Claro as chief of the FDA Oncology Center of Excellence is pivotal. His focus on modernizing regulatory practices aims to expedite drug approvals while ensuring that innovative treatments reach patients more swiftly. However, the FDA's decision to delay approval for Exelixis' tyrosine kinase inhibitor with Roche's Tecentriq underscores the complexities involved in novel therapies' assessments. On the geographical front, Singapore's launch of a biotech hub in Boston highlights the global nature of biotech development. This move strengthens historical ties and emphasizes international collaboration's importance in accelerating scientific research. In clinical trials, AbbVie's success with Qulipta (atogepant) for menstrual migraine prevention is noteworthy. It not only expands therapeutic options for women but also underscores a growing focus on gender-specific health issues within clinical research. Meanwhile, new RAS-targeting therapies continue to emerge as Revolution Medicines' Rasonque gains approval for advanced pancreatic cancer treatment—a significant milestone in addressing previously undruggable mutations. Industry dynamics are further illustrated by leadership changes at major firms like Takeda. The departure of long-time R&D chief Andy Plump often signals strategic shifts that could influence research priorities and corporate focus. Novartis recently faced setbacks with late-stage asset failures impacting its market position and raising investor concerns about its strategic direction concerning mergers and acquisitions. On a similar note, Takeda undergoes organizational changes amid potential strategic shifts following its CEO appointment—demonstrating volatility within companies striving for competitive advantage through effective leadership. Promising developments at the FDA include solidifying leadership with Karim Mikhail at CBER and Michael Davis at CDER—crucial appointments ensuring operational stability amidst past disruptions under former commissioner Marty Makary—and appointing Jared Seehafer as deputy commissioner focusing on AI integration into regulatory processes. Significant financial movements continue highlighting investor interest: Frazier adds over $1 billion targeting small-mid-sized biotech firms while Samsung Biologics secures manufacturing deals emphasizing strategic partnerships' importance globally. Scientific developments also reveal challenges; Silence Therapeutics maintains polycythemia vera leadership despite emerging hurdles while Novo Nordisk halts heart disease studies reflecting complexities validating interleukin-6 as therapeutic targets. AI integration gains momentum transforming operational efficiencies across various functions from R&D to human resources optimizing overall effectiveness within life sciences organizations—a trend poised to reshape people strategy profoundly impacting medical affairs evidenced evaluations enhancing decision-making processes ultimately improving patient outcomes significantly moving forward amidst this dynamic industry landscape filled with opportunities and risks requiring agility and forward-thinking strategies to capitalize on emerging scenarios efficiently and effectively ensuring continued success thriving amidst transformations occurring rapidly around us today, tomorrow, and beyond!Support the show

Brought to you by the English Programme. Featuring news, politics, popular culture, celebrity trivia, quizzes, book readings, and a whole host of fun.Support Our Rescue Cats | Our Blog | Get New Episodes By Email | Rumble | X | YouTube | NewsK365 on Spreaker | Get New Blog Posts By Email | Throne Wishlist |

Former Fidelity president and MFS chairman Bob Pozen joins Excess Returns to discuss retirement investing, the risks in private credit, and why he favors a 90% stock and 10% cash portfolio for investors who can cover their living expenses without selling stocks.Drawing on decades in asset management, he shares lessons from Peter Lynch and Warren Buffett, explains why index funds are difficult to beat, and challenges conventional thinking about bonds, Social Security, and corporate earnings reporting.Bob Pozen's websitehttps://www.bobpozen.comFollow Bob Pozen on Twitterhttps://x.com/PozenResearch discussed:Consequences of Mandatory Quarterly Reporting: The U.K. Experiencehttps://papers.ssrn.com/sol3/papers.cfm?abstract_id=2817120Rating Without Market Disciplinehttps://papers.ssrn.com/sol3/papers.cfm?abstract_id=6859158Giving Life to Private (Rated) Credithttps://papers.ssrn.com/sol3/papers.cfm?abstract_id=6857958Topics covered:What investors misunderstand about Peter Lynch and how fund liquidity shaped his approach versus Warren Buffett's.Lessons from leading Fidelity and rebuilding investor trust at MFS after its trading scandal.Why fees, fund size, and market efficiency make large-cap index funds difficult to beat.Private equity in 401(k) plans, liquidity constraints, and the problem with instant valuation markups.How private credit ratings and affiliated investments can obscure risks on insurance company balance sheets.Pozen's proposals for Social Security reform and the consequences of postponing difficult decisions.How automatic IRA enrollment could expand retirement savings access for workers without employer plans.Why Pozen favors a 90/10 portfolio for certain investors and how spending needs and inheritance goals affect allocation.Why quarterly financial reporting and quarterly earnings guidance deserve different treatment.The behavioral cost of chasing rallies and selling downturns, plus Pozen's work on AI and personal productivity.Timestamps:00:00 Peter Lynch, Warren Buffett, and staying the course05:27 Leading Fidelity and keeping stock funds invested11:03 Rebuilding trust at MFS after the trading scandal16:01 Why active managers struggle to beat index funds20:03 Private equity in 401(k)s and valuation concerns24:45 Private credit ratings and insurance company risks29:33 Regulatory gaps and affiliated insurance investments35:51 Social Security reform and the cost of waiting40:00 Automatic IRAs for workers without retirement plans44:09 The case for 90% stocks and 10% cash50:05 Why quarterly financial reporting matters55:00 The problem with precise quarterly earnings guidance59:00 Avoiding emotional market timing and AI productivity toolsLearn more about the Excess Returns podcast network:https://excessreturns.coNo information discussed in this podcast should be construed as investment advice. Securities discussed may be held by the hosts and guests, their firms or their clients.

Send money home with Taptap Send and use promo code BEERBICEPS on your first transfer to receive a bonus.This offer is available to new users only. Users in the US and Canada must send 100 or more on their first transfer to qualify for the bonus.Bonus amounts:USA: $20 USDCanada: $20 CADEuropean Union: €10United Kingdom: £10Australia: $30 AUDTo view the full list of supported countries and terms, visit: https://www.taptapsend.com/en Regulatory disclaimers:Taptap Send Australia Pty Ltd (ABN 21 675 932 386) Australian Financial Services Licence No. 559468.TapTap Send Payments Co., licensed as a Money Transmitter by the Banking Department of the State of New York. NMLS ID: 2108069------------------Follow Mandar Khaladkar Guru Ji's Social Media Handles:-Instagram: https://www.instagram.com/mandarkhaladkar2008Facebook: https://www.facebook.com/share/1DW4m4wCov/YouTube: https://www.youtube.com/@UCiceTkS20YG1NJ9i03tN3mg https://www.youtube.com/@UCa9fX7pls_j738kv2N_eiUQ WhatsApp Channel:- https://whatsapp.com/channel/0029VaT5TtYAzNbvzeu07z0lCheck out BeerBiceps SkillHouse Courses Here - https://linktr.ee/bbskillhouseFor all BeerBiceps vlog content Watch Life Of BeerBiceps - https://www.youtube.com/@BeerbicepsuncutDownload my meditation and wellness app, Swa:aha.https://app.level.game/?c=zSbmYn----------------In this 539th (overall 1044th) episode of TRS, we sit down with Ganapati sadhak Mandar Khaladkar Guruji to explore the deeper spiritual meaning of Lord Ganesha, his presence in the Vedas, and the role of Ganapati upasana in everyday life. Explore the deeper meaning of Ganapati tattva from devotion, sadhana, and mantra chanting to the connection between Lord Ganesha, the Muladhara Chakra, and kundalini.This conversation also covers the Ganapati Atharvashirsha, visarjan, Anant Chaturdashi, Lokmanya Tilak's role in Ganeshotsav, different forms of Ganapati, mantra practice, and the truth behind beliefs about Ganesha's trunk direction.A simple yet insightful guide to experiencing Ganesh Chaturthi with greater devotion, awareness, and spiritual understanding.00:00 - Ganesh Ji Sadhna Special04:14 - Sadhak vs Normal Devotee Mindset07:27 - Science of Japa & Chanting10:00 - Spiritual Tests & Growth Through Japa11:32 - Vakratunda Mahakaya Meaning12:02 - Lokmanya Tilak & Sarvajanik Ganeshotsav15:10 - Significance of Anant Chaturdashi17:08 - Understanding Divine Tatva18:23 - Bringing Ganpati Home: Rituals & Bhav22:00 - The Emotional Bond During Visarjan24:55 - What Is Atharvashirsha?26:18 - Lord Ganesha in the Vedas & Yugas29:15 - Saguna vs Nirguna Ganpati32:06 - Kasba Ganpati Secrets34:41 - Ganesha, Intellect & the Chakras37:16 - Muladhara Chakra & 5-Minute Sadhana41:17 - Kundalini & Sound Vibrations45:38 - Sanskrit Sounds & Rhythms in Chanting55:08 - Samaveda & Sacred Melodies Demonstration1:00:20 - Spiritual Meaning of Ganpati Pandals1:06:23 - Energy in Different Ganesha Temples1:07:07 - Trunk Direction Myth: Right vs Left1:12:15 - How to Start Ganesha Sadhana1:18:02 - Ganesha Gita & True Karma1:22:34 - Guruji's Message for Youth

Program description: China Business Uncovered takes listeners inside China's corporate world through the eyes of reporters who investigate it firsthand. Featuring open conversations with Caixin journalists, each episode breaks down the most complex developments inside Chinese businesses. Tune in to understand how critical stories are covered, what's really happening beneath the surface, and why it matters for businesses and investors operating in and around China. Recorded in Mandarin and produced in English with the help of AI, China Business Uncovered brings Caixin's in-depth investigative reporting to a global audience. Episode intro: For years, so-called youth correctional institutions and "growth camps" have operated across China, marketing themselves to families struggling with mental health issues, school refusal, teenage relationships and parent-child conflict. Some charge desperate parents hundreds of thousands of yuan, while referring students between programs for hefty commissions. But students who were put through the programs told Caixin that "intervention" involved forced physical training, beatings, psychological abuse and restricted contact with the outside world. In this episode of China Business Uncovered, host Han Wei speaks with Caixin reporter Fan Qiaojia about how these institutions turn parental anxiety into business, why some families keep paying, and how regulatory gaps have allowed the industry to survive repeated scandals and crackdowns. Chapters: (02:55) Young victims emerge (08:32) A lucrative referral network (12:10) How camps take advantage of dysfunctional families (18:02) Why parents turn to unregulated programs (21:24) Regulatory gaps leave victims nowhere to turn This episode of China Business Uncovered was based on this story: In Depth: The Dark Side Behind China's Youth 'Correction' Industry Produced by Kelsey Cheng, Han Wei and Du Bohan. Unlock exclusive discounts with a Caixin group subscription — ideal for teams and organizations. Save an extra $50. Introductory offer for new readers. Subscribe now.

The future of the Consumer Financial Protection Bureau (CFPB or Bureau) has rarely been more uncertain. Since its creation, the CFPB has been at the center of intense political and policy debate, with its priorities changing dramatically as administrations change. The events of the past year or so under the leadership of Acting Directors chosen by President Trump, however, have taken that policy whiplash to a new level. In our latest Consumer Finance Monitor podcast released today, Alan Kaplinsky (the founder and former leader for 25 years of the Consumer Financial Services Group at our firm) was joined by two former CFPB officials with decades of experience inside the Bureau: Jason Brown, a visiting fellow at the Brookings Institution and former CFPB Assistant Director for Research, and David Silberman, former Acting Deputy Director and longtime Associate Director for Research, Markets and Regulation. We discussed their recent Brookings commentary, "The CFPB: Where to Go From Here," which proposes a series of structural reforms designed to make the Bureau a more stable and effective financial regulator. Their recommendations are noteworthy not because they seek to preserve every aspect of the CFPB as it has operated in the past. Rather, they focus on a more fundamental question: How can the CFPB carry out its statutory mission while allowing presidential administrations to pursue different policy agendas without repeatedly dismantling and rebuilding the agency? Consumer Finance Monitor is hosted by Alan Kaplinsky, Senior Counsel at Ballard Spahr, and the founder and former chair of the firm's Consumer Financial Services Group. We encourage listeners to subscribe to the podcast on their preferred platform for weekly insights into developments in the consumer finance industry.

Law firms are navigating evolving regulation, hybrid working models, ambitious growth strategies, and rapid advances in cloud and AI technology. Modernizing client intake and matter onboarding can help firms connect these priorities while improving the experience for partners, compliance teams, and clients. In this episode, Marie-Claire Grace O'Reilly, Industry Principal, Legal Compliance at Intapp joins host Alex Pillow to explore law firms can bring together people, processes, data, and technology to create more connected, efficient, and risk-aware client onboarding. Key topics covered: Regulatory change and AML readiness AI agents in client onboarding and compliance Data quality and interoperability Cloud transformation in law firms Improving partner and client experience The future of legal operations and AI Additional resources: Moody's x Intapp partnership page Intapp's resource library Moody's professional services page To learn more about Moody's please visit our website or get in touch; we would love to hear from you. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Sandoz's recent move to invest $2.5 billion in creating a vertically integrated biosimilar manufacturing network is making waves across the industry. This significant investment underscores the growing importance of biosimilars as cost-effective alternatives to biologics. With plans to develop 100 biosimilars by 2040, Sandoz is strategically positioning itself to meet increasing global demand for affordable treatments. This initiative not only enhances their production capabilities but also aligns with the push from healthcare systems worldwide for more economical care options. The vertical integration model promises to streamline production, reduce supply chain issues, and maintain high-quality standards, reinforcing Sandoz's competitive position in the biosimilars market. Meanwhile, Amgen has achieved a noteworthy milestone with its drug Imdelltra (tarlatamab-dlle), which met its Phase 3 overall survival endpoint for extensive-stage small-cell lung cancer (SCLC) maintenance therapy. Imdelltra, a bispecific T-cell engager targeting DLL3, represents a novel approach in oncology, potentially setting a new standard of care for SCLC patients who have severely limited treatment options. The positive trial results could lead to regulatory approval, broadening access to this innovative therapy and potentially improving patient outcomes significantly. Regulatory stability is on the horizon with the FDA appointing permanent heads for its Center for Biologics Evaluation and Research (CBER) and Center for Drug Evaluation and Research (CDER). This leadership continuity is crucial as it supports the agency's ongoing restructuring efforts aimed at enhancing efficiency and oversight. Stable leadership within these centers ensures rigorous drug evaluation processes continue, which is critical for timely approvals and has a direct impact on drug developers' strategic planning and market entry timelines. Clinical trials continue to yield varied results, showcasing the inherent uncertainties in drug development. AstraZeneca's Tozorakimab showed promise with approximately a 30% reduction in exacerbations in Phase 3 trials for chronic obstructive pulmonary disease (COPD), hinting at improved management of respiratory diseases through targeted monoclonal antibody therapies. Conversely, challenges persist as Evommune's Evo756 did not meet its Phase 2b trial expectations for atopic dermatitis, and Tyra Biosciences' Dabogratinib fell short in non-muscle invasive bladder cancer trials—highlighting the unpredictable nature of clinical research. Investment flows into biopharmaceuticals remain robust, with Encoded Therapeutics raising $275 million to advance its gene therapy program for Dravet syndrome. Similarly, Luma Group has secured $410 million for ventures focusing on ophthalmology and cellular rejuvenation technologies. Such investments reflect strong confidence in gene and cell therapies' transformative potential on patient care. On the mergers and acquisitions front, Sernova Biotherapeutics' merger with Seraxis to form Betanova Biotherapeutics exemplifies how companies are consolidating expertise to enhance R&D capabilities and expand their market reach, particularly in cell therapy solutions for diabetes management. These strategic consolidations indicate ongoing efforts to leverage synergies that could redefine therapeutic landscapes. The biopharmaceutical sector is also seeing shifts due to ongoing geopolitical tensions between the U.S. and China, pushing companies to seek investment opportunities outside China. This diversification strategy aims to mitigate geopolitical risks while continuing global innovation efforts. In obesity treatment research, partnerships like those between GemPharmaTech signal new frontiers beyond GLP-1 receptor agonists. These collaborations highlight an industry commitment to tackling global health challenges with innovative therapies that prioritize efficacy and safety. These developments collectively paint a picture of a dynamic industry marked by scientific breakthroughs, strategic investments, regulatory evolution, and significant challenges in clinical trials. As these sectors evolve, they promise exciting advancements that could profoundly redefine global healthcare paradigms. The focus remains on overcoming therapeutic barriers through sustained research efforts and innovative approaches—a testament to the industry's relentless pursuit of improving patient care outcomes worldwide.Support the show

Aaron interviews David Aronchick, CEO @ Expanso (former PM lead for Kubernetes, Kubeflow co-founder, and open-source ML leader at Azure) about how open source is reshaping the AI infrastructure stack. Aronchick recounts his path from early Linux and enterprise work to launching Kubernetes and GKE, then creating Kubeflow in 2017 to orchestrate end-to-end ML workflows on Kubernetes. The discussion centers on gaps in AI infrastructure, especially reproducibility and determinism across hardware, drivers, OS, packages, and data lineage, arguing Kubernetes alone can't fully solve it. They contrast open weights with true open-source models, noting that real openness would require reproducible training data and infrastructure. They explore “AI-native” enterprise architecture, the role of open-source harnesses/wrappers to add deterministic controls, and growing edge/distributed compute needs driven by governance, compliance, bandwidth, and hybrid deployment realities.SHOW: 1061SHOW TRANSCRIPT: The Enterprise AI Show #1061 TranscriptSHOW VIDEO: https://youtu.be/kpQg3YIIUL8SHOW LINKS:Expanso homepageTechArena, "Expanso's David Aronchick on Data Gravity and Pipeline Debt": Open at Intel podcast, "Data Privacy and Efficiency with Bacalhau Compute Over Data"SHOW SPONSORS:NordLayer - Use ENTERPRISE10 for 10% offNasuni - Activate your data for AI and request a demoSHOW TOPICS:You have a super interesting background (First managing PM for Kubernetes, Co-founded Kubeflow, led open-source ML at Microsoft Azure). Give everyone a brief introduction and how you became so involved in open-source and the EnterpriseOSS topics:Back when we were The Cloudcast, we covered K8s in depth, but I'm not sure we ever did a show on Kubeflow. Kubeflow tried to bring Kubernetes-style orchestration to ML workflows. Looking back, what did that generation of open-source AI infrastructure get right, and what did it miss that the current wave (agents, inference at the edge) is now having to solve for again? Oh, and maybe give a quick intro to Kubeflow as well for those that aren't familiarZooming out - open source shaped your whole career, from Kubernetes to Kubeflow to Bacalhau. Where do you think open source has the most leverage in the AI infrastructure stack right now, and where do you think it's losing ground to closed, vendor-controlled platforms?What are your thoughts on “OSS models”? Today, OSS really means open weights. Do you think there will ever be a truly OSS model? What would it take? Thoughts on the state of the industry?A couple of Enterprise “grab bag” questions for you on a few different topics while we have you:"AI-native" gets used a lot and means different things to different people. What does AI-native actually mean for enterprise architecture in your view, and how is it different from just bolting AI onto an existing cloud or data stack?Regulatory and data residency pressure keeps coming up across industries (telecom, healthcare, financial services). How much of the edge/distributed compute push is being driven by AI performance needs versus governance and compliance requirements? Which one is the bigger driver right now?CLOSING: If anyone is interested, what's the best way to get started?FEEDBACK?Email: show @ the enterprise ai show dot comBluesky: @TheEntAIShow.bsky.socialTwitter/X: @TheEntAIShowInstagram: @TheEntAIShow

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we unveil a series of transformative strides in drug approvals, clinical trials, and regulatory landscapes that are reshaping the future of patient care. AstraZeneca's camizestrant, now branded as Etcamah, has received FDA approval for treating ESR1-mutated hormone receptor-positive, HER2-negative advanced breast cancer. This approval is a testament to the potential of selective estrogen receptor degraders (SERDs) in oncology. The Phase 3 trial results highlight camizestrant's efficacy when combined with CDK4/6 inhibitors, offering a tailored therapeutic strategy for patients with ESR1 mutations. Such advancements in personalized oncology are steering the industry toward more precise treatment paradigms. Complementing this approval, Guardant Health's Guardant360 CDx has been sanctioned as a companion diagnostic tool for camizestrant. The liquid biopsy-based method precisely identifies ESR1 mutations, underscoring the growing reliance on precision diagnostics in cancer management. As precision medicine continues to evolve, integrating diagnostics with therapeutics becomes crucial in achieving optimal patient outcomes. Bristol Myers Squibb has made headlines with its CAR-T cell therapy, arlocabtagene autoleucel, showing efficacy in its Phase 3 trial for GPRC5D-targeted relapsed or refractory multiple myeloma. This advancement reflects the burgeoning application of cell-based treatments in hematological malignancies and signals a shift towards personalized immunotherapy strategies promising improved patient outcomes. On a related note, Brainchild Bio's significant $116 million fundraising initiative aims to advance CAR-T therapies tailored for childhood brain cancers. This development highlights the potential of CAR-T technology beyond hematologic cancers and indicates an intensified focus on pediatric oncology therapeutics. In regulatory news, Shionogi's cefiderocol has gained approval from Australia's Therapeutic Goods Administration (TGA) for combating carbapenem-resistant gram-negative bacterial infections. Cefiderocol addresses critical needs in combating multidrug-resistant pathogens, particularly in urinary tract infections, and highlights ongoing global efforts to tackle antimicrobial resistance. Clinical trials continue to yield promising outcomes. Pharvaris' deucrictibant showcased positive results in its Phase 3 trial for hereditary angioedema by effectively targeting the bradykinin B2 receptor. Novo Nordisk's semaglutide (Wegovy) demonstrated remarkable efficacy in reducing obesity among children during its Phase 3 trials. These results emphasize continued innovation in treating metabolic disorders and rare diseases by leveraging small molecule therapeutics and receptor modulators. Not all developments have been positive. Novartis and Ionis Pharmaceuticals faced setbacks with pelacarsen failing to meet endpoints in a Phase 3 trial aimed at reducing major cardiovascular events despite lowering lipoprotein(a). This underscores the challenges of translating promising biomarkers into effective therapeutic interventions. Regulatory challenges were also observed as American Regent recalled batches of epinephrine due to contamination issues, and Boston Scientific recalled spinal cord implants linked to serious injuries. These instances underscore the importance of stringent quality control and regulatory compliance to ensure patient safety. Meanwhile, Amgen's DLL3-targeted therapy, Imdelltra, achieved an overall survival win in a first-line setting for small cell lung cancer (SCLC), although specific numerical results were not disclosed. This bispecific antibody could set a new standard for early intervention in SCLC, emphasizing the potential of targeted therapies in improving survival rates for aggressive cancers. In other advancements, Roche continues to dominate neurology with top positions in corporate reputation rankings within this therapeutic area. This accolade reflects Roche's commitment to innovation and patient-centric approaches to managing neurological disorders. As these developments unfold across various domains of pharmaceutical innovation and regulation, they collectively signal a dynamic era for the industry marked by rapid scientific progress and evolving treatment strategies. The implications are profound, offering potential improvements in patient outcomes through more targeted therapies while highlighting challenges such as clinical trial failures that necessitate continued diligence in drug development strategies. As these trends unfold, they hold promise for significant advancements in treatment efficacy and safety across various therapeutic areas. Thank you for tuning into Pharma Daily. Stay informed about the latest industry developments as we continue to explore the dynamic landscape of pharmaceutical innovations together.Support the show

How do you know whether your MedTech commercialisation strategy is actually working?Regulatory approval, clinical evidence, distributor appointments, customer meetings and even your first sale can all feel like signs of commercial progress. But for MedTech founders trying to build, commercialise and eventually export a medical device, there's a difference between creating the conditions for commercial success and proving you have a sustainable business. In this episode, Hakeem uses an unlikely lesson from 90s hip-hop to explore what really counts as commercial success—and why the ability to repeat a sale matters so much.In this episode you'll discover:How to distinguish between activities that support MedTech commercialisation and the evidence that your commercial model is actually working.Why making your first medical device sale is only part of the story—and what repeatability tells you about whether you've built a sustainable business.How working backwards from the money can help you understand the decision-makers, budgets, beliefs and buying process required to generate sales repeatedly.ActionListen now to discover how to measure whether your MedTech commercialisation strategy is genuinely working and identify what needs to happen to turn individual sales into a repeatable commercial model.Book a 30min Healthcare Export Accelerator discovery callMessage me via DM on LinkedinThis podcast is for clinicians and solo founders feeling stuck in turning their medical devices into real businesses, with practical insight on go to market strategy, sales strategy, product launch, sales plans, business growth, exporting, selling internationally and how to scale up their international sales in MedTech.

In this episode, Frank La Vigne sits down with Sandeep Pauddar, Head of Digital Trust at DQS, to explore the fast-evolving world of digital trust, compliance, and data security. From the growing complexities of global regulations, to the increasing intersection of AI, cybersecurity, and enterprise risk, Sandeep Pauddar shares real-world stories—including personal experiences with AI-driven phishing—and breaks down how organizations can foster a security-aware culture. Whether you're leading a startup or a global enterprise, tune in for actionable insights on building digital trust, navigating the compliance landscape, and why organizational leadership plays a crucial role in keeping data secure.LinksSandeep on LinkedIn -https://www.linkedin.com/in/sandeep-pauddar/DQS Global -https://www.dqsglobal.com/Extreme Ownership -https://amzn.to/4zZRiH8Get a Free Audible Book -https://www.audible.com/ep/creator?afsrc=1&source_code=PDTGBPD060314004RWatch on YouTube -https://www.youtube.com/watch?v=dF4D5hYM7YwTime Stamps00:00 Introduction and guest welcome05:00 AI data security in various industries06:44 Department collaboration on AI and compliance10:58 Information security standards overview14:23 Balancing Innovation and Standardization18:14 Navigating global AI regulations22:14 Regulatory advice for startup founders25:33 Discussing common patterns in failures28:24 Discussing link metadata in apps33:09 Security threats and personal story37:11 Challenges in adopting security systems38:32 Insurance and breach response policies43:21 Promoting Extreme Ownership on Audible45:01 Finding more about Claude Academy

In this episode, Cereasa Horner, Vice President of Payment Integrity and Governance at CERIS, discusses how health plans can adapt to accelerating regulatory changes, strengthen documentation and audit readiness, and improve alignment with providers. She also shares strategies for cross-functional collaboration, transparency and an education-first approach to payment integrity.This episode is sponsored by CERIS.

Stephen Miran is a former governor of the Federal Reserve, a former chairman of the Council of Economic Advisers under President Donald J. Trump, and currently a senior strategist for Hudson Bay Capital Management. In Steve's third appearance on the show, he discusses his life as chair of the Council of Economic Advisers and as a Federal Reserve governor, the Fed's balance sheet, regulatory dominance, the future of the discount window, the possible return of monetarism, and much more. Watch the full length video on our new YouTube Channel! Check out the transcript for this week's episode, now with links. Recorded on August 20th, 2026 Subscribe to David's Substack: Macroeconomic Policy Nexus Follow David Beckworth on X: @DavidBeckworth Follow Stephen Miran on X: @SteveMiran Follow the show on X: @Macro_Musings Check out our Macro Musings merch! Timestamps 00:00:00 - Intro 00:01:42 - Life as CEA Chair 00:08:40 - Reducing the Fed's Balance Sheet 00:42:23 - A Return to Monetarism? 00:54:32 - Outro

Dr. Judith Borger breaks down what peptides actually are at the molecular level, unpacks the fast-moving and often confusing FDA regulatory landscape around peptide compounding in 2026, and gives an evidence-based rundown of the most talked-about peptide products and stacks — including “Glow” (GHK-Cu), “Wolverine” (BPC-157/TB-500), CJC-1295/Ipamorelin, PT-141, and the GLP-1s. In This Episode: What peptides are and how they differ from proteins and amino acids Why some peptides act as hormones, antioxidants, or signaling molecules in the body The current FDA regulatory status of peptide compounding, including the 503A Bulk Drug Substances List and the 2026 Pharmacy Compounding Advisory Committee review Why “removed from the safety watch-list” is not the same as “approved for compounding” The difference between a peptide from a licensed compounding pharmacy versus an unregulated online vendor A breakdown of popular peptide products: Glow (GHK-Cu, glutathione, and vitamin C — sometimes also including BPC-157 and TB-500), Wolverine (BPC-157 + TB-500), CJC-1295/Ipamorelin, PT-141 (bremelanotide/Vyleesi), and GLP-1s (semaglutide, tirzepatide) Why “Glow” and “Wolverine” aren't always separate products — some Glow formulations fold in the same BPC-157/TB-500 combination sold as Wolverine What real human clinical evidence exists for each — and where the evidence is limited to animal studies or mechanistic theory Disclaimer: This episode is for educational purposes only and does not constitute medical advice. Regulatory status discussed reflects information available as of August 2026 and is subject to change; listeners should confirm current FDA guidance and consult a licensed physician before considering any peptide therapy. Dr. Judith Borger Links: www.theaestheticdoctor.com www.instagram.com/doctorborger

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of pivotal advances and industry dynamics that are shaping the future of healthcare. The U.S. Food and Drug Administration has recently granted approval to Ionis Pharmaceuticals' Zanvastro, a breakthrough in treating Alexander disease. This condition, a rare neurodegenerative disorder caused by mutations in the glial fibrillary acidic protein gene, has historically posed significant treatment challenges. Zanvastro, an antisense oligonucleotide therapy, is notable for being the first of its kind to target this protein, marking a monumental step in precision medicine. The success of this therapy not only opens new avenues for treating Alexander disease but also highlights the potential of antisense technologies to address other rare genetic disorders. Ionis Pharmaceuticals is poised to further explore this innovative therapeutic approach in other neurodegenerative conditions like Angelman syndrome, reinforcing their leadership in targeting rare genetic diseases at the molecular level. Meanwhile, strategic partnerships continue to transform the metabolic disease treatment landscape. The Menarini Group's partnership with Gan & Lee Pharmaceuticals aims to bring the GLP-1 receptor agonist Bofanglutide to European markets. This collaboration underscores the growing emphasis on GLP-1 therapies for managing type 2 diabetes and obesity. With an investment of $72 million upfront and potential milestone payments reaching $771 million, this partnership illustrates the strategic importance of cross-border collaborations in accelerating drug availability and leveraging regional expertise. In parallel, Argo Biopharma has announced promising phase 2 results for its small interfering RNA therapy targeting plasma prekallikrein in hereditary angioedema. This innovative approach offers a prophylactic treatment option for a disease characterized by severe swelling attacks. By harnessing RNA interference mechanisms, Argo Biopharma joins a broader movement within biotech towards gene-silencing technologies that tackle previously challenging conditions. Further emphasizing innovation, Superluminal Medicines has raised $60 million to advance its AI-discovered MC4R-targeting drug for rare obesity conditions. This initiative highlights the transformative potential of artificial intelligence in drug discovery, enabling rapid identification of therapeutic candidates by analyzing extensive datasets and predicting molecular interactions. The focus on rare forms of obesity reflects a broader trend toward personalized medicine, where treatments are increasingly tailored to specific genetic profiles. Regulatory developments also feature prominently with Liquidia Corporation receiving FDA fast track designation for Yutrepia, an inhaled small molecule aimed at treating systemic sclerosis-related Raynaud's phenomenon. This designation will expedite the development and review process for Yutrepia, facilitating quicker access to this potentially life-enhancing treatment for those suffering from autoimmune complications. However, challenges persist within the industry. The FDA issued a warning letter to Fresenius Medical Care over deficiencies related to complaint handling and contamination inspections for sterile injectable products. This action underscores ongoing concerns regarding compliance with safety standards and highlights the critical need for rigorous quality control mechanisms to ensure patient safety. In exploring new therapeutic modalities, psilocybin has shown promise in managing neuropathic pain through preclinical studies. These findings add to the growing body of evidence supporting psychedelics' potential benefits beyond mental health applications, opening new avenues for pain management therapies that could revolutionize treatment protocols. The competitive landscape in weight management sees significant movement with Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo vying for dominance in oral GLP-1 receptor agonists. As companies race to develop more patient-friendly formulations, these innovations promise to significantly boost adherence and outcomes in obesity management. Lastly, industry trends reveal an evolving marketing landscape where social media collaborations and strategic partnerships are becoming central to engaging patients and advocating medical conditions. For example, Novartis' partnership with a British Olympian aims to enhance multiple sclerosis advocacy by leveraging influential platforms for patient education and empowerment. These developments paint a picture of a dynamic pharmaceutical and biotech sector characterized by scientific innovation, strategic partnerships, regulatory vigilance, and data-driven approaches. As companies continue to navigate these complexities, their ability to leverage cutting-edge technologies and foster global collaborations will be crucial in delivering transformative health solutions. The industry's focus on precision medicine and novel therapeutic modalities promises significant advancements in patient care and disease management in the years ahead. Thank you for joining us at Pharma Daily—your source for the latest news shaping the world of pharmaceuticals and biotechnology.Support the show

Show Notes: Chaudhry, S., & Kulkarni, C. (2021). Design patterns of investing apps and their effects on investing behaviors. In Proceedings of the 2021 ACM Designing Interactive Systems Conference (DIS '21) (pp. 777–788). https://doi.org/10.1145/3461778.3462008 Dickinson, D. (2026). Dark patterns and consumer protection law for app makers. Consumer Law Review. https://www.researchgate.net/publication/400702824_Dark_Patterns_and_Consumer_Protection_Law_for_App_Makers Farronato, C., Fong, J., & Larkin, I. (2025). Designing consent: Choice architecture and consumer welfare. Management Science. https://doi.org/10.1145/3736252.3742627 International Organization of Securities Commissions. (2023). Online choice architecture: How digital design is used to influence investors (IOSCO PD794). https://www.iosco.org/news/pdf/IOSCONEWS688.pdf Kahneman, D. (2011). Thinking, fast and slow. Farrar, Straus and Giroux. Lai, L. (2024). Playful finance: Gamification and intermediation in fintech. Journal of Financial Regulation, 10(1), 1–35. https://doi.org/10.1016/j.jfr.2023.100174 Lusardi, A., & Mitchell, O. S. (2014). The economic importance of financial literacy: Theory and evidence. Journal of Economic Literature, 52(1), 5–44. https://doi.org/10.1257/jel.52.1.5 Madrian, B. C., & Shea, D. F. (2001). The power of suggestion: Inertia in 401(k) participation and savings behavior. Quarterly Journal of Economics, 116(4), 1149–1187. https://doi.org/10.1162/003355301753265543 Mathur, A., Mayer, J., & Kshirsagar, M. (2019). Dark patterns at scale: Findings from a crawl of 11K shopping websites. Proceedings of the ACM on Human-Computer Interaction, 3(CSCW), 1–32. https://doi.org/10.1145/3359183 Rakovic, M., & Inal, Y. (2023). Dark finance: Exploring deceptive design in investment apps. International Journal of Human-Computer Studies, 170, Article 102944. https://doi.org/10.1016/j.ijhcs.2022.102944 UK Financial Conduct Authority. (2024, July). Review of online choice architecture and vulnerability [Regulatory discussion paper]. https://www.citizensadvice.org.uk/policy/publications/review-of-online-choice-architecture-and-vulnerability/ Savitha, B., & Hawaldar, I. T. (2022). What motivates individuals to use FinTech budgeting applications? Evidence from India during the COVID-19 pandemic. Cogent Economics & Finance, 10(1). https://doi.org/10.1080/23322039.2022.2127482 Thaler, R. H. (2015). Misbehaving: The making of behavioral economics. W. W. Norton & Company. Thaler, R. H., & Sunstein, C. R. (2008). Nudge: Improving decisions about health, wealth, and happiness. Yale University Press. Veigas, P. (2023). A comprehensive analysis of the user experience in digital platforms concerning the practice of nudging user behaviour. Journal of Behavioral and Experimental Economics, 104, Article 101986. https://doi.org/10.1016/j.socec.2023.101986 Report a Dark Pattern with the FDIC: https://reportfraud.ftc.gov/

What Americans eat is changing, but consumer food trends affect much more than what ends up in the grocery cart. Changes in nutrition policy, affordability, convenience, health trends, and consumer perceptions can ultimately ripple throughout the food system and all the way back to farmers and ranchers.On this episode of North American Ag Spotlight, Chrissy Wozniak speaks with Susan Backus, Vice President of Regulatory and Scientific Affairs at the Meat Institute, about the changing American diet and what those shifts mean for animal agriculture.Susan explains how nutrition conversations have evolved from a narrow focus on individual nutrients like fat and cholesterol toward a broader discussion about nutrient density and overall dietary patterns. She also discusses the renewed consumer interest in protein, noting that meat provides much more than protein alone, with nutrients including iron, zinc, selenium, vitamin B12, vitamin B6, thiamin, niacin, and potassium.  The conversation also explores the sometimes surprising gap between what consumers say they want and what they actually purchase. Susan points to recent consumer research showing that while shoppers express concern about food processing, convenience has risen to become one of the leading factors influencing food purchases, alongside taste and price. Chrissy and Susan discuss the influence federal dietary guidance can have far beyond individual food choices, including school meals, hospitals, the military, nutrition education, food service, and product innovation. Susan also explains why the Meat Institute believes effective dietary guidance should meet consumers where they are and help people make realistic, incremental improvements rather than recommendations they are unlikely to maintain. Looking ahead, Susan identifies the growing use of GLP-1 medications as one trend that could significantly affect food consumption. As some consumers eat smaller quantities of food, she believes nutrient density may become even more important and could create new opportunities for naturally nutrient-dense animal protein products. The episode also previews Susan's appearance at the Women in Agribusiness Summit in New Orleans, where she will participate in the Food Consumption Trends and Nutrition Policy Panel. Susan explains why bringing perspectives from across agriculture together is critical to breaking down industry silos and building stronger relationships throughout the food and agriculture value chain. Send us Fan MailSchedule a demo today at ecorobotix.com Introducing FarmNewsDaily.com - your source for agriculture news!Subscribe to North American Ag at https://northamericanag.com

Patrick McGarry, Federal CDO at ServiceNow and author of The Adaptive Organization, has spent years watching organizations accumulate data and tools but fail to convert them into decisions. Overhead grows. Outcomes don't. Hence “Intelligence Without Action Is Just Overhead.” Patrick joins Juan and Tim to walk through why federal data programs stall (the idea-to-deployment lag is long enough that the tech moves on), why incentives matter more than mandates, and why the right question should not be "how do we get AI ready" and instead should be "how do we make our organization accountable for AI." Topics discussed: Intelligence vs. action Ownership and outcomes Federal government's speed problem The CATALOG framework: Culture & Talent, Analytics & AI, Technology & Architecture, Alignment, Leadership & Governance, Operations & Delivery, Growth & Measurement. Governance as clarity, not bureaucracy Open standards, vendor lock-in, semantics, interoperability Regulatory standards as a double-edged sword See omnystudio.com/listener for privacy information.

Medical device regulation continues to evolve across multiple markets. For manufacturers, the challenge isn't simply following every new publication—it's understanding which developments require action, which ones need monitoring, and how they affect existing regulatory strategies.This latest Medical Device Made Easy regulatory update reviews selected developments from July and August 2026 across Europe, Switzerland, the UK, United States, India, Singapore, and Brazil.

Amazon and Meta Platforms are facing increased scrutiny from regulators and states and that's not only affecting their stock price, it could affect their business long-term. We discuss whether FTC probes and settlements are a big deal long-term. We end by laying out what John Ternus needs to do to get off on the right foot at Apple. Travis Hoium, Lou Whiteman, and Matt Frankel discuss: - Amazon vs FTC- Future of Amazon Retail- Meta's Settlement- Is Meta Becoming Bit Tobacco?- John Ternus' First Day- How Apple Can succeed Companies discussed: Amazon (AMZN), Apple (AAPL), Meta (META). Host: Travis HoiumGuests: Lou Whiteman, and Matt FrankelEngineer: Kristi Waterworth Advertisements are sponsored content and provided for informational purposes only. The Motley Fool and its affiliates (collectively, “TMF”) do not endorse, recommend, or verify the accuracy or completeness of the statements made within advertisements. TMF is not involved in the offer, sale, or solicitation of any securities advertised herein and makes no representations regarding the suitability, or risks associated with any investment opportunity presented. Investors should conduct their own due diligence and consult with legal, tax, and financial advisors before making any investment decisions. TMF assumes no responsibility for any losses or damages arising from this advertisement. We're committed to transparency: All personal opinions in advertisements from Fools are their own. The product advertised in this episode was loaned to TMF and was returned after a test period or the product advertised in this episode was purchased by TMF. Advertiser has paid for the sponsorship of this episode. Learn more about your ad choices. Visit ⁠⁠⁠⁠⁠⁠megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

Commissioner Hester Peirce joins the podcast to discuss Regulation Crypto Assets, as well as secondary market trading, DePIN and vaults. If you haven't listened to the full Reg Crypto explainer, that's episode 207. This episode is presented by Altitude. Visit altitude.xyz/law to learn more about their financial operating system.Timestamps:0:00 Intro2:22 Secondary transactions3:23 Promises and representations5:05 Essential managerial efforts8:27 Regulatory arbitrage10:29 Form TR16:59 Existing token projects and Form TR18:27 Compliance costs21:48 Secondary markets24:12 DePIN27:02 Vaults35:31 Accredited investors40:25 Tokens and equityThank you to the other sponsors of this episode: Cahill Gordon & Reindel, the Solana Policy Institute and the Hyperliquid Policy Center.On Thursday, September 24, 2026, CahillNXT will host Confluence 2026, its flagship conference, in New York City. This year's theme, Leading the NXT Frontier, brings together regulators, institutional investors, founders, policymakers and industry leaders to examine digital assets, market structure, regulation and the emerging technologies transforming financial markets. To register your interest, email events@cahill.com. Newsletter: Stay updated on emerging tech law for free at lawofcode.fm. Any feedback on this episode? Or how to improve the podcast? Click here: https://forms.gle/yFFN66e8iy8shQkAA Disclaimer: This podcast is for informational and educational purposes only and does not constitute legal or investment advice. Commissioner Peirce's views are her own and do not necessarily represent those of the SEC or her fellow Commissioners. Listening to this podcast does not create an attorney-client relationship.

The American Health Information Management Association (AHIMA) and the Association of Clinical Documentation Integrity Specialists (ACDIS), an HCPro professional community, have released the 2026 update to Guidelines for Achieving a Compliant Query Practice.The practice brief's guidance applies equally across inpatient, outpatient, ambulatory, and professional fee environments, with specific considerations for outpatient and ambulatory contexts noted throughout.During this exclusive Talk Ten live edition broadcast, Rebecca Hendren, ACDIS director, and Laurie Prescott, RN, MSN, CCDS, CCDS-O, CDIP, former interim ACDIS director, will discuss the process for updating the guidance and share insight about the 2026 updates.

What if the bottleneck in cell line development isn't how many clones you screen, but how you track them?Cloning workflows have long relied on brute force: screen more cells, automate harder, and hope that small-scale performance predicts manufacturability. But too often, the “perfect” clone in a 96-well plate turns into a dud when it reaches the bioreactor. That disconnect costs time, money, and promising therapies.This week, host David Brühlmann welcomes Kent Rapp, Co-founder and CEO of Biolinco, an entrepreneur who's turning the classic approach to cell line development inside out. Drawing from his background in chemical engineering and his work in biomanufacturing at Johns Hopkins University, Kent teamed up with DNA barcoding experts to pioneer a new workflow: barcode every cell, pool them, and track their true performance in the environment that matters.Topics discussed:The pitfalls of brute-force screening in traditional cell line development (03:05)Kent's background and how he was drawn to combine science, startups, and biomanufacturing (04:37)Overcoming discrepancies between small-scale and large-scale screening environments (08:30)How DNA barcoding allows for high-resolution, pooled clone screening (10:34)Sensitivity advantages of sequencing over plate-based detection (14:21)Methodology for tracking and recovering individual high-performing clones from pools (15:13)Impact on speed and workflow efficiency in cell line development (17:31)Regulatory and safety considerations related to DNA barcodes in cell lines (19:04)Smart insight: According to Kent, biotech as an industry has a tendency to "automate problems instead of solve them". Rather than addressing the root causes—like lack of meaningful measurements at relevant scales—companies often throw more robots and more plates at the issue, hoping brute force will finally yield the magical clone. But real process improvement requires a rethinking of what is being measured and how those insights are generated—not just a higher throughput of the same flawed assay.If this got you rethinking how you screen clones, you'll want these next. We've tackled cell line development, high-throughput screening, and the art of spotting manufacturable candidates early from a few different directions — here are four worth queuing up.Episodes 117 - 118 : Cell Line Development Secrets: Eliminating Critical Bottlenecks for Faster Timelines with Andrea GoughEpisodes 09 - 10: Revolutionizing Cell-Line Development: Unleashing the Power of Nanopens and Microenvironments with Tanner NevillEpisodes 123 - 124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan SharfsteinEpisodes 115 - 116: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy AgrestiConnect with Kent Rapp:LinkedIn: www.linkedin.com/in/kent-rapp Biolinco website: www.biolinco.comFree 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it hereSupport the show

Russell Gold on the regulatory moats blocking the transmission needed to move renewable power across state lines, little changed since his 2019 interview.

In this episode of Medsider Radio, we sat down with Deanna Harshbarger, CEO of Cala Health.Cala Health developed the Cala kIQ® System, a prescription wearable therapy for action hand tremor.Deanna holds a degree in chemical engineering and brings more than 20 years of commercial medtech experience to Cala. Before joining the company, she held senior leadership roles at Johnson & Johnson, Boston Scientific, and Medtronic, and helped develop and commercialize technologies across interventional cardiology, neuromodulation, and diabetes care.In this conversation, Deanna shares how she empowers leadership teams to execute, building clinical evidence step-by-step, how patient observation shapes product development, and why raising capital is both a sprint and a marathon.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Deanna Harshbarger, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(03:34) - Deanna's journey from J&J, Boston Scientific, and Medtronic to Cala Health (08:16) - How Cala personalized therapy around each patient's unique experience (11:53) - Operating lessons Deanna carried from strategics to startups (22:27) - The unboxing interview that changed Cala's product design (29:16) - How Cala balanced feasibility studies, RCTs, and real-world evidence after its commercial launch (34:33) - Years of clinical evidence helped Cala win reimbursement for a new therapy (38:52) - The case for holding back when you're ready to commercialize (44:30) - Why fundraising is both a sprint and a marathon

SUMMARY: Brian, Brandon, and Aaron focus on AI watermarking, driven largely by EU transparency requirements, and discuss how approaches like token-selection patterns can be detected but were reportedly cracked quickly with tools that strip watermarks. Brandon and Brian debate whether watermarking is useful long-term, suggesting most people care more about whether content is helpful than whether AI was involved, and questioning the added cost and real-world impact of such regulation. They also explore implications for education policies that ban AI use, changing assessment methods to curb cheating, and potential enterprise and government procurement issues where “no AI” requirements could trigger disputes and lawsuits, while AI review may also level the playing field in contract understanding.SHOW: 1058SHOW TRANSCRIPT: The Enterprise AI Show #1058 TranscriptSHOW VIDEO: https://youtu.be/6zlN_oIR5XcSHOW LINKS:Anthropic WatermarkingClaude Support on WatermarkingSHOW SPONSORS:Nasuni - Activate your data for AI and request a demoTopic: Anthropic recently started invisibly watermarking all Claude-generated text and files (Aug 11), joining Google (SynthID) and ~190 companies that signed the EU's AI Act Transparency Code. Article 50 became enforceable August 2, with fines up to €15M or 3% of global turnover for non-compliance. Within 24 hours of Anthropic's announcement, a free tool to strip Claude's watermark showed up on GitHub.Core question: Is watermarking building durable AI provenance infrastructure, or is it a regulatory checkbox that breaks the moment someone runs a paraphraser?Discussion angles:The cat-and-mouse problem: Watermarks degrade with editing/paraphrasing/translation by design; light edits survive, heavy rewrites don't. Is a signal that vanishes under normal use actually useful, or just plausible deniability for labs?Regulatory arbitrage: EU forces the mandate, but xAI hasn't signed the voluntary Code. What happens to companies operating in the gap, and does the EU rule become a de facto global standard the way GDPR did?What it's actually good for: Not a lie detector, a provenance/tamper flag. Useful for enterprise content authenticity and platform moderation pipelines, much less useful for catching a student or a bad actor who just runs one rewrite pass.FEEDBACK?Email: show @ the enterprise ai show dot comBluesky: @TheEntAIShow.bsky.socialTwitter/X: @TheEntAIShowInstagram: @TheEntAIShow

There is a strange thing happening in rental housing across the United States.If you looked only at national statistics, you might conclude that the business of owning an apartment is largely unchanged. Since January 2025, more than forty states have passed, published, or court-decided something that touches deposits, notices, fees, or evictions. Each individual change can look small.Taken together, they represent something much larger.---------**Real Estate Espresso Podcast:** Spotify: [The Real Estate Espresso Podcast](https://open.spotify.com/show/3GvtwRmTq4r3es8cbw8jW0?si=c75ea506a6694ef1)   iTunes: [The Real Estate Espresso Podcast](https://podcasts.apple.com/ca/podcast/the-real-estate-espresso-podcast/id1340482613)   Website: [www.victorjm.com](http://www.victorjm.com)   LinkedIn: [Victor Menasce](http://www.linkedin.com/in/vmenasce)   YouTube: [The Real Estate Espresso Podcast](http://www.youtube.com/@victorjmenasce6734)   Facebook: [www.facebook.com/realestateespresso](http://www.facebook.com/realestateespresso)   Email: [podcast@victorjm.com](mailto:podcast@victorjm.com)  **Y Street Capital:** Website: [www.ystreetcapital.com](http://www.ystreetcapital.com)   Facebook: [www.facebook.com/YStreetCapital](https://www.facebook.com/YStreetCapital)   Instagram: [@ystreetcapital](http://www.instagram.com/ystreetcapital)  

In this episode, Holly Buckley, Chair of Healthcare at McGuireWoods, discusses the latest healthcare private equity trends, including transaction volume, physician practice investments, AI adoption, state regulations and the outlook for deals and exits. Overview – McGuireWoods Healthcare Growth & Operations Conference 2026. Online registration by Cvent